Industry Briefs: November 5, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Agere Pharmaceuticals has expanded its cGMP spray-dry capabilities. Read More
Charles River has agreed to acquire a majority ownership of Vital River. Read More
Cytovance Biologics has been awarded a biopharmaceutical development and manufacturing contract by Fountain BioPharma. Read More
Eli Lilly has announced a $140-million expansion to the company’s Indianapolis insulin manufacturing operations. Read More
Integrated Project Services has opened a new office São Paulo, Brazil. Read More
Pharmalink has entered into a contract with Patheon for the manufacturing of Nefecon, for treating the underlying pathology of progressive IgA nephropathy, the most common form of primary glomerulonephritis and a leading cause of end-stage renal disease.
Wacker Biotech and XL-protein have agreed to produce PASylated biopharmaceuticals. Read More
People News
Astellas has named Jeffrey Bloss vice-president of scientific and medical affairs. Read More
Cedarburg Hauser Pharmaceuticals has appointed John K. Lynch as chief scientific officer. Read More
Patheon has appointed Michael Lehmann as head of global pharmaceutical development services. Read More
Teva has announced several changes to its executive leadership team. Allan Oberman has been named president and CEO of Teva Americas Generics, and Jill DeSimone has been appointed as senior vice-president and general manager of Teva Global Women’s Health. William S. Marth will retire as president and CEO of Teva Americas. Read More
Following its acquisition of Actavis, Watson has announced a new global generics management team, including Siggi Olafsson, as president of the division, and several other appointments. Read More
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
